Perennial malaria chemoprevention (PMC) is newly formulated strategy endorsed in June 2022 by the World Health Organization and builds off the previously recommended but poorly implemented strategy of intermittent preventive treatment of malaria in infants – IPTi. IPTi – the provision of single dose Sulphadoxine Pyrimethamine (SP) delivered through the Expanded Program of Immunization (EPI) at times of childhood immunisation at approximately 3, 4 and 9 months of age was shown to provide infants with protection against malaria, anaemia and all cause hospital admissions.

Related Keywords

Benin , Ghana , Nepal , Cameroon , East Timor , Tanzania , Mozambique , Zambia , Switzerland , Uganda , Swiss , David Schellenberg , Jayne Webster , Lilly Claire , Lily Claire Ekobika , Elsa Nhantumbo , Branwen Owen , Master In Public Health , Program Of Immunization , Global Malaria Programme , World Health Organization , Public Health In Developing Countries , International Health , Programme Evaluation , Public Health , Malaria Capacity Development Consortium , Malaria Consortium , London School Of Hygiene , Population Services International , Sulphadoxine Pyrimethamine , Expanded Program , Plus Project , London School , Tropical Medicine , Science Adviser , Malaria Programme , Preferred Product Characteristics , Intervention Modelling , Claire Ekobika , Senior Coordinator , Country Lead , Program Manager , Developing Countries ,